Background And Purpose: The study will test the hypothesis that preventive topical steroid treatment instituted from start of radiotherapy can ameliorate acute radiation dermatitis. Subgroups of increased risk of dermatitis are included.
Material And Methods: A double blinded randomized trial in patients with breast cancer receiving adjuvant radiotherapy (RT) after surgery. In total, 202 patients were randomized to betamethasone-17-valerate cream or Essex® cream, a moisturizer. Treatment was assessed by RTOG clinical scoring. Patients' symptoms were recorded. The analyses were stratified for RT schedules as well as for anatomical sites, skin type, breast size and BMI. Patients treated the irradiated area during the radiation period and two weeks following cessation of radiation.
Results: Patients receiving hypofraction RT developed less skin reactions than those treated with conventional RT. Treatment with a potent steroid resulted in clinically and statistically significantly less skin reactions (p<0.001) regardless of RT schedule. The effect of the steroid was prominent in all subgroups.
Conclusion: Prophylactic treatment with a strong local steroid is efficient for the prevention and control of acute radiation dermatitis in breast cancer patients treated with adjuvant RT, independent of RT schedule. Preventive application of a potent corticosteroid cream should be used in the routine and instituted at the start of RT.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.radonc.2016.11.013 | DOI Listing |
Rev Med Suisse
January 2025
Service d'oncologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
New therapeutic agents in oncology are emerging rapidly, both in terms of the number of approved drugs and the technological and biological innovation of new treatments. Antibody-drug conjugates (ADC) offer a promising cancer therapy by specifically targeting tumor cells. ADC are composed of a monoclonal antibody recognizing the tumor cell via specific antigens, coupled with a potent cytotoxic agent that resembles classical chemotherapy.
View Article and Find Full Text PDFFront Immunol
January 2025
Instituto de Investigaciones Bioquímicas de La Plata "Prof. Dr. Rodolfo R. Brenner", (INIBIOLP), Universidad Nacional de La Plata (UNLP) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), La Plata, Argentina.
Introduction: Gastropod hemocyanins are potent immunostimulants in mammals, a trait associated with their large molecular size and unusual glycosylation patterns. While the hemocyanin from the marine snail keyhole limpet (KLH), has been widely studied and successfully employed as a carrier/adjuvant in several immunological applications, as well as a non-specific immunostimulant for bladder cancer treatment, few other gastropod hemocyanins have been biochemically and immunologically characterized. In this work, we investigated the immunogenic properties of the hemocyanin from (PcH), an invasive south American freshwater snail.
View Article and Find Full Text PDF3 Biotech
February 2025
Department of Life Sciences and Biotechnology, Chhatrapati Shahu Ji Maharaj University Kanpur, Kanpur, Uttar Pradesh India.
Tuberculosis (TB) is one of the leading causes of death in the world, despite being a preventable and curable disease. Irrespective of tremendous advancements in early detection and treatment, this disease still has high mortality rates. This is due to the development of antibiotic resistance, which significantly reduced the efficacy of antibiotics, rendering them useless against this bacterial infection.
View Article and Find Full Text PDFHuman RNA ligase 1 (Rlig1) catalyzes the ligation of 5'-phosphate to 3'-hydroxyl ends a conserved three-step mechanism. Rlig1-deficient HEK293 cells exhibit reduced cell viability and RNA integrity under oxidative stress, suggesting Rlig1's role in RNA repair maintenance. Reactive oxygen species (ROS) are linked to various diseases, including neurodegenerative disorders and cancer, where RNA damage has significant effects.
View Article and Find Full Text PDFInt J Nanomedicine
January 2025
School of Medicine, South China University of Technology, Guangzhou, Guangdong, People's Republic of China.
Background: Exosomes sourced from mesenchymal stem cells (MSC-EXOs) have become a promising therapeutic tool for sepsis-induced myocardial dysfunction (SMD). Our previous study demonstrated that Apelin pretreatment enhanced the therapeutic benefit of MSCs in myocardial infarction by improving their paracrine effects. This study aimed to determine whether EXOs sourced from Apelin-pretreated MSCs (Apelin-MSC-EXOs) would have potent cardioprotective effects against SMD and elucidate the underlying mechanisms.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!